Clinical hold on Achillion drug may not be released,
Jul 2 at 07:50
Profile hits: NONE
After the FDA placed Achillion's HCV drug sovaprevir on clinical hold
based on its negative interaction with an HIV drug in a study, the firm thinks
the clinical hold may not be released. The firm believes that Achillion will
have trouble finding a partner for sovaprevir, and it reiterates a Perform
rating on the stock.
Achillion downgraded to Hold from Buy at Maxim
Jul 2 at 07:42
Profile hits: QU2
Maxim downgraded Achillion after the FDA issued a clinical hold for
sovaprevir. The firm says coming back from clinical holds have historically been
difficult for HCV therapies.